146 related articles for article (PubMed ID: 30601319)
61. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study.
Fournier JP; Sommet A; Bourrel R; Oustric S; Pathak A; Lapeyre-Mestre M; Montastruc JL
Eur J Clin Pharmacol; 2012 Nov; 68(11):1533-40. PubMed ID: 22527348
[TBL] [Abstract][Full Text] [Related]
62. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis.
Dai YN; Wang JH; Zhu JZ; Lin JQ; Yu CH; Li YM
Cancer Causes Control; 2015 Sep; 26(9):1245-55. PubMed ID: 26081426
[TBL] [Abstract][Full Text] [Related]
63. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.
Gadzhanova S; Roughead EE; Bartlett LE
Eur J Clin Pharmacol; 2016 Jun; 72(6):765-71. PubMed ID: 26961086
[TBL] [Abstract][Full Text] [Related]
64. Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study.
Márquez PHP; Torres OH; San-José A; Vidal X; Agustí A; Formiga F; López-Soto A; Ramírez-Duque N; Fernández-Moyano A; Garcia-Moreno J; Arroyo JA; Ruiz D;
Drugs Aging; 2017 Jun; 34(6):453-466. PubMed ID: 28432600
[TBL] [Abstract][Full Text] [Related]
65. Renin-angiotensin system blockade use and risks of cognitive decline and dementia: A meta-analysis.
Zhuang S; Wang HF; Li J; Wang HY; Wang X; Xing CM
Neurosci Lett; 2016 Jun; 624():53-61. PubMed ID: 27163195
[TBL] [Abstract][Full Text] [Related]
66. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
Bangalore S; Fakheri R; Toklu B; Ogedegbe G; Weintraub H; Messerli FH
Mayo Clin Proc; 2016 Jan; 91(1):51-60. PubMed ID: 26763511
[TBL] [Abstract][Full Text] [Related]
67. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
68. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
[TBL] [Abstract][Full Text] [Related]
69. Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension.
Levi-Marpillat N; Macquin-Mavier I; Tropeano AI; Parati G; Maison P
Hypertens Res; 2014 Jun; 37(6):585-90. PubMed ID: 24671016
[TBL] [Abstract][Full Text] [Related]
70. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
71. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
[TBL] [Abstract][Full Text] [Related]
72. Use of Antihypertensive Drugs and Ischemic Stroke Severity - Is There a Role for Angiotensin-II?
Hwong WY; Bots ML; Selvarajah S; Abdul Aziz Z; Sidek NN; Spiering W; Kappelle LJ; Vaartjes I
PLoS One; 2016; 11(11):e0166524. PubMed ID: 27846309
[TBL] [Abstract][Full Text] [Related]
73. [Influence of Renin-angiotensin System Blockage on Recurrence of Non-muscle-invasive Bladder Cancer].
Bai YJ; Wang XM; Han P; Yang YB; Tang Y; Wei Q; Wang J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):635-639. PubMed ID: 30378319
[TBL] [Abstract][Full Text] [Related]
74. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
75. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
76. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
[TBL] [Abstract][Full Text] [Related]
77. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
[TBL] [Abstract][Full Text] [Related]
78. Trends and patterns of five antihypertensive drug classes between 2007 and 2012 in China using hospital prescription data.
Xu H; He Y; Xu L; Yan X; Dai H
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):430-7. PubMed ID: 25828638
[TBL] [Abstract][Full Text] [Related]
79. Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink.
Hagberg KW; Sahasrabuddhe VV; McGlynn KA; Jick SS
Pharmacotherapy; 2016 Feb; 36(2):187-95. PubMed ID: 26846893
[TBL] [Abstract][Full Text] [Related]
80. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
